These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 27906438)

  • 21. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis.
    Matsunaga S; Kishi T; Iwata N
    Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25548104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Huperzine A for Alzheimer's disease.
    Li J; Wu HM; Zhou RL; Liu GJ; Dong BR
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005592. PubMed ID: 18425924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials.
    Tsoi KK; Hirai HW; Chan JY; Kwok TC
    J Am Med Dir Assoc; 2016 Jan; 17(1):24-30. PubMed ID: 26392193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
    Gauthier S; Molinuevo JL
    Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Anti-Dementia Drugs in Relation to Change in Cognition, Behavior, and Functioning in Alzheimer's Disease over a Three-Year Period: Kuopio ALSOVA Study.
    Törmälehto SM; Martikainen JA; Väätäinen ST; Hallikainen IT; Hallikainen M; Bell JS; Koivisto AM
    J Alzheimers Dis; 2015; 48(4):1033-41. PubMed ID: 26444756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex and gender differences in the treatment of Alzheimer's disease: A systematic review of randomized controlled trials.
    Canevelli M; Quarata F; Remiddi F; Lucchini F; Lacorte E; Vanacore N; Bruno G; Cesari M
    Pharmacol Res; 2017 Jan; 115():218-223. PubMed ID: 27913252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current approaches in the treatment of Alzheimer's disease.
    Shah RS; Lee HG; Xiongwei Z; Perry G; Smith MA; Castellani RJ
    Biomed Pharmacother; 2008; 62(4):199-207. PubMed ID: 18407457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis.
    Wang HF; Yu JT; Tang SW; Jiang T; Tan CC; Meng XF; Wang C; Tan MS; Tan L
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):135-43. PubMed ID: 24828899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease.
    Popp J; Arlt S
    Curr Opin Psychiatry; 2011 Nov; 24(6):556-61. PubMed ID: 21934621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
    Wattmo C; Minthon L; Wallin ÅK
    Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
    Tayeb HO; Yang HD; Price BH; Tarazi FI
    Pharmacol Ther; 2012 Apr; 134(1):8-25. PubMed ID: 22198801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis.
    Wang J; Yu JT; Wang HF; Meng XF; Wang C; Tan CC; Tan L
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):101-9. PubMed ID: 24876182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction.
    Shahim B; Xu H; Haugaa K; Zetterberg H; Jurga J; Religa D; Eriksdotter M
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):128-136. PubMed ID: 38224338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives].
    Blain H; Jouzeau JY; Blain A; Terlain B; Tréchot P; Touchon J; Netter P; Jeandel C
    Presse Med; 2000 Feb; 29(5):267-73. PubMed ID: 10701410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA
    Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic options in Alzheimer's disease.
    Moreira PI; Zhu X; Nunomura A; Smith MA; Perry G
    Expert Rev Neurother; 2006 Jun; 6(6):897-910. PubMed ID: 16784412
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.